Evoke Pharma Quarterly Income Statements Chart
Quarterly
|
Annual
Evoke Pharma Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| net product sales | 2,654,186 | 2,551,366 | 1,735,490 | 1,675,994 | 1,562,860 | 1,131,368 | 810,408 | 796,370 | 832,100 | 461,795 | 418,380 | 360,571 | 930,449 | 236,635 | 90,421 | ||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||
| cost of goods sold | 104,024 | 41,478 | 92,529 | 59,024 | 34,908 | 57,357 | 50,591 | 190,084 | 89,775 | 67,774 | 22,760 | 136,679 | 58,435 | 68,253 | 64,751 | ||||||||||||||||
| research and development | 11,677 | 4,645 | 22,560 | 92,357 | 66,990 | 27,207 | 40,388 | 191,478 | 41,717 | 35,723 | 81,699 | 195,229 | 277,825 | 103,846 | 205,032 | 5,782,094 | 463,853 | 641,542 | 822,444 | 1,205,599 | 746,882 | 695,360 | 625,497 | 1,388,791 | |||||||
| selling, general and administrative | 3,824,142 | 3,733,450 | 3,139,536 | 3,482,328 | 3,131,389 | 2,766,077 | 2,847,940 | 2,288,861 | 2,614,488 | 2,315,175 | 2,405,075 | 1,735,524 | 2,635,161 | 2,142,149 | 2,338,295 | ||||||||||||||||
| total operating expenses | 3,939,843 | 3,774,928 | 3,236,710 | 3,563,912 | 3,166,297 | 2,915,791 | 2,965,521 | 2,506,152 | 2,744,651 | 2,574,427 | 2,469,552 | 1,907,926 | 2,775,295 | 2,405,631 | 2,680,871 | 2,232,106 | 2,079,610 | 6,964,966 | 1,793,687 | 1,424,158 | 1,636,662 | 2,123,738 | 1,969,895 | 1,768,420 | 1,522,557 | 2,306,096 | |||||
| income from operations | -1,285,657 | -1,223,562 | -1,501,220 | -1,887,918 | -1,603,437 | -1,784,423 | -2,155,113 | -1,709,782 | -1,912,551 | -2,112,632 | -2,051,172 | -1,547,355 | -1,844,846 | -2,168,996 | -2,590,450 | -2,209,086 | -2,079,610 | -6,964,966 | -1,793,687 | -1,424,158 | -1,636,662 | -2,123,738 | -1,969,895 | -1,768,420 | -1,522,557 | -2,306,096 | |||||
| yoy | -19.82% | -31.43% | -30.34% | 10.42% | -16.16% | -15.54% | 5.07% | 10.50% | 3.67% | -2.60% | -20.82% | -29.95% | -11.29% | -68.86% | 44.42% | 55.12% | 27.06% | 227.96% | -8.95% | -19.47% | 7.49% | -7.91% | |||||||||
| qoq | 5.07% | -18.50% | -20.48% | 17.74% | -10.14% | -17.20% | 26.05% | -10.60% | -9.47% | 3.00% | 32.56% | -16.13% | -14.94% | -16.27% | 17.26% | 6.23% | -70.14% | 288.30% | 25.95% | -12.98% | -22.93% | 7.81% | 11.39% | 16.15% | -33.98% | ||||||
| operating margin % | |||||||||||||||||||||||||||||||
| other income: | |||||||||||||||||||||||||||||||
| interest income | 99,294 | 81,001 | 46,058 | 26,544 | 35,558 | 41,164 | 35,331 | 32,588 | 24,714 | 3,910 | 795 | 1,019 | 1,421 | 3,011 | 3,164 | 776 | 1,033 | 485 | 3,378 | 5,930 | 8,597 | 9,642 | 4,629 | 7,788 | 3,089 | 2,903 | |||||
| interest expense | -126,027 | -124,657 | -124,658 | -126,027 | -126,028 | -124,658 | -123,288 | -126,027 | -126,027 | -124,658 | -123,288 | -126,026 | -126,027 | -124,658 | -123,339 | -59,552 | -50,528 | -2,914 | |||||||||||||
| total other income | -26,733 | -43,656 | -78,600 | -93,439 | -101,313 | -120,748 | -122,493 | -125,007 | -124,606 | -121,647 | -15,045 | -58,776 | -49,495 | -2,429 | 3,378 | 5,930 | 8,597 | 9,642 | 4,629 | 7,788 | 3,089 | 2,903 | |||||||||
| net income | -1,312,390 | -1,267,218 | -1,579,820 | -1,987,401 | -1,693,907 | -1,867,917 | -2,243,070 | -1,803,221 | -2,013,864 | -2,233,380 | -2,173,665 | -1,672,362 | -1,969,452 | -2,290,643 | -2,605,495 | -2,267,862 | -2,129,105 | -6,967,395 | -1,790,309 | -1,418,228 | -1,628,065 | -2,114,096 | -1,965,266 | -1,760,632 | -1,519,468 | -2,303,193 | |||||
| yoy | -22.52% | -32.16% | -29.57% | 10.21% | -15.89% | -16.36% | 3.19% | 7.82% | 2.26% | -2.50% | -16.57% | -26.26% | -7.50% | -67.12% | 45.53% | 59.91% | 30.78% | 229.57% | -8.90% | -19.45% | 7.15% | -8.21% | |||||||||
| qoq | 3.56% | -19.79% | -20.51% | 17.33% | -9.32% | -16.72% | 24.39% | -10.46% | -9.83% | 2.75% | 29.98% | -15.08% | -14.02% | -12.08% | 14.89% | 6.52% | -69.44% | 289.17% | 26.24% | -12.89% | -22.99% | 7.57% | 11.62% | 15.87% | -34.03% | ||||||
| net income margin % | |||||||||||||||||||||||||||||||
| net income per share | -0.94 | -0.93 | -0.17 | -0.59 | -0.51 | -0.56 | -0.67 | -0.53 | -0.6 | -0.71 | -0.07 | -0.06 | -0.06 | -0.07 | -0.08 | -0.09 | -0.08 | -0.28 | -0.07 | -0.06 | -0.07 | -0.09 | -0.11 | -0.1 | -0.09 | -0.14 | |||||
| weighted-average shares used for eps calculation | 1,399,882 | 1,363,525 | 9,082,139 | 3,343,070 | 3,343,070 | 3,343,070 | 3,343,070 | 3,143,626 | 3,343,070 | 3,156,925 | 32,777,294 | 32,185,758 | 32,542,481 | 32,386,004 | 31,158,065 | 25,492,169 | 26,146,220 | 24,987,975 | 24,439,881 | 22,296,089 | 24,128,060 | 23,258,567 | 17,484,318 | 16,602,422 | 17,129,649 | 16,425,468 | |||||
| total other | -65,480.25 | -90,470 | -83,494 | -87,957 | |||||||||||||||||||||||||||
| forgiveness of paycheck protection loan and accrued interest | 105,130 | ||||||||||||||||||||||||||||||
| general and administrative | 1,096,821 | 1,874,578 | 1,182,872 | 1,329,834 | 782,616 | 814,218 | 918,139 | 1,223,013 | 1,073,060 | 897,060 | 917,305 | ||||||||||||||||||||
| gain from change in fair value of warrant liability | |||||||||||||||||||||||||||||||
| change in fair value of warrant liability | 108,348 |
We provide you with 20 years income statements for Evoke Pharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Evoke Pharma stock. Explore the full financial landscape of Evoke Pharma stock with our expertly curated income statements.
The information provided in this report about Evoke Pharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.